FDA Brief

Warning letters Drugs

FDA warning letter to

Denison Pharmaceuticals, LLC

High riskIssued Jul 26, 2023Posted Aug 15, 2023Division of Pharmaceutical Quality Operations I

Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.

What happened

FDA inspected Denison's Lincoln, RI drug manufacturing facility from January 5 to February 9, 2023 and found inadequate investigations into lubricant contamination, foul-odor/microbial failures, and water-system excursions; it also found no diethylene glycol/ethylene glycol identity testing for glycerin and propylene glycol and unvalidated rapid microbial test methods. FDA also reviewed labels and websites for Colic Calm, Colic Calm +, and Nauzene Kids and found them to be unapproved new drugs. After FDA recommended removing batches made during lubricant use, the company recalled four products in May 2023.

What FDA found

  1. The company did not thoroughly investigate batch failures and complaints, including lubricant contamination, foul-odor batches with too-numerous-to-count yeast/mold, and water-system microbial excursions.

    21 CFR 211.192
  2. The company did not perform identity testing for every lot of glycerin and propylene glycol to detect diethylene glycol (DEG) and ethylene glycol (EG).

    21 CFR 211.84(d)(1)
  3. The company used an unvalidated rapid microbiological test method and released lots despite failing results.

    21 CFR 211.165(e)
  4. The company marketed Colic Calm, Colic Calm +, and Nauzene Kids as drugs without FDA-approved applications.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)

What FDA wants

FDA asks Denison to correct the violations promptly and provide comprehensive independent assessments and remediation plans for investigations, corrective and preventive action (CAPA), the water system, component testing, and laboratory methods, plus a risk assessment for DEG/EG and recall actions for affected lots; no response deadline is stated in the provided text.

Who should pay attention

  • companies using Denison as a contract manufacturer
  • retailers and distributors of Colic Calm, Nauzene Kids, or recalled products
  • drugmakers that use glycerin or propylene glycol

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk